Clinical Trial

Neoadjuvant Therapy of SBRT Sequencial With Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC Patients(neoR-TORCH)

Study acronym: neoR-TORCH
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a randomized, controlled, multi-center, phase III clinical study to evaluate the efficacy and safety of SBRT sequencial with Toripalimab and chemotherapy versus Toripalimab and chemotherapy for subjects with resectable, stage II-III NSCLC.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-05-26; most recent amendment 2026-05-08.
Status change: Not Yet Recruiting → Recruiting 2025-03-10
Trial Details
NCT Number NCT06437977
Lead Sponsor Shanghai Chest Hospital
Conditions Stage II-III Non-small Cell Lung Cancer
Enrollment 478 participants
Start Date 2024-09-12
Primary Completion 2027-06 (estimated)
Study Completion 2029-06 (estimated)
Updated on ClinicalTrials.gov 2026-05-13